AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
PRINCETON, N.J., Aug. 22, 2017 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12, 2017 at 9:10 AM ET in New York.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. Follow Agile on social media: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.
Contact: Mary Coleman - 609-683-1880
